Patents by Inventor Takumi Teratani

Takumi Teratani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10561122
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: February 18, 2020
    Assignees: SUMITOMO CHEMICAL COMPANY, LIMITED, National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Patent number: 10087421
    Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: October 2, 2018
    Assignees: OTSUKA PHARMACEUTICAL FACTORY, INC., JICHI MEDICAL UNIVERSITY
    Inventors: Eiji Kobayashi, Tamaki Wada, Yasutaka Fujita, Norihiro Yoshinaga, Masako Doi, Yasuhiro Fujimoto, Takumi Teratani
  • Publication number: 20170311578
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 2, 2017
    Applicants: DS Pharma Biomedical Co., Ltd., National Cancer Center
    Inventors: Takumi TERATANI, Takahiro OCHIYA
  • Patent number: 9700023
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: July 11, 2017
    Assignees: DS Pharma Biomedical Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Publication number: 20140109247
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicants: National Cancer Center, Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Takumi TERATANI, Takahiro OCHIYA
  • Patent number: 8628957
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 14, 2014
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Publication number: 20130260461
    Abstract: The present invention provides a mammalian stem cell suspension containing mammalian stem cells and at least one polysaccharide such as trehalose, and the like; a mammalian stem cell aggregation inhibitor containing polysaccharide such as trehalose, and the like; a method of suppressing aggregation of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharide; an inhibitor of a decrease in the survival rate of mammalian stem cells containing polysaccharide such as trehalose and the like; a method of suppressing a decrease in the survival rate of mammalian stem cells, containing suspending the mammalian stem cells in an aqueous physiological solution containing polysaccharides, and the like.
    Type: Application
    Filed: November 9, 2011
    Publication date: October 3, 2013
    Applicants: JICHI MEDICAL UNIVERSITY, OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Eiji Kobayashi, Tamaki Wada, Yasutaka Fujita, Norihiro Yoshinaga, Masako Doi, Yasuhiro Fujimoto, Takumi Teratani
  • Publication number: 20120142092
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Application
    Filed: February 10, 2012
    Publication date: June 7, 2012
    Applicants: NATIONAL CANCER CENTER, DAINIPPON SUMITOMO PHARMA CO., LTD.
    Inventors: Takumi TERATANI, Takahiro OCHIYA
  • Patent number: 8137966
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: March 20, 2012
    Assignees: Dainippon Sumitomo Pharma Co., Ltd., National Cancer Center
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Patent number: 7736893
    Abstract: Objects to be achieved by the invention are to provide a nanobio device in which cultured cells are organized at a high-level in a state near in vivo, and to provide a method of using the nanobio device of imitative anatomy structure. The nanobio device of imitative anatomy structure of the invention is obtained by manufacturing a substrate with a bio-compatible substance and arranging a plurality of types of cells thereon in a desired array. A method of manufacturing a nanobio device in the invention includes a step of manufacturing a substrate for a nanobio device by a micromachine processing technique and a step of arranging a plurality of cultured cells on the substrate in a desired array with laser optical tweezers.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: June 15, 2010
    Assignees: SII Nanotechnology Inc.
    Inventors: Masanao Munekane, Hiroyuki Wada, Kouji Iwasaki, Toshiaki Fujii, Takahiro Ochiya, Yusuke Yamamoto, Takumi Teratani
  • Patent number: 7332336
    Abstract: The present invention provides methods for inducing the differentiation of pluripotent cells. The present inventors succeeded in differentiating hepatocytes from ES cells without EB formation, using simple adherent monoculturing in media comprising several growth factors in culture dishes with two different matrices.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: February 19, 2008
    Assignee: Effector Cell Institute, Inc.
    Inventors: Takahiro Ochiya, Takumi Teratani
  • Publication number: 20070186293
    Abstract: The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like.
    Type: Application
    Filed: March 1, 2005
    Publication date: August 9, 2007
    Applicant: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Takumi Teratani, Takahiro Ochiya
  • Publication number: 20060188946
    Abstract: objects to be achieved by the invention are to provide a nanobio device in which cultured cells are organized at a high-level in a state near in vivo, and to provide a method of using the nanobio device of imitative anatomy structure. The nanobio device of imitative anatomy structure of the invention is obtained by manufacturing a substrate with a bio-compatible substance and arranging a plurality of types of cells thereon in a desired array. A method of manufacturing a nanobio device in the invention includes a step of manufacturing a substrate for a nanobio device by a micromachine processing technique and a step of arranging a plurality of cultured cells on the substrate in a desired array with laser optical tweezers.
    Type: Application
    Filed: February 14, 2006
    Publication date: August 24, 2006
    Inventors: Masanao Munekane, Hiroyuki Wada, Kouji Iwasaki, Toshiaki Fujii, Takahiro Ochiya, Yusuke Yamamoto, Takumi Teratani
  • Publication number: 20060154235
    Abstract: The present invention provides modified methods of producing human hepatocyte-like cells which exhibit phenotypes more similar to those of human hepatocytes. The present invention also provides the human hepatocyte-like cells and uses thereof. The methods of the present invention comprises a prolonged incubation period and addition of dexamethasone to the culture medium. The methods of the inventors produce human hepatocyte-like cells whose morphology is more similar to that of human hepatocytes, compared with the conventional system. The cells produced have both morphological and functional features of primary culture cells from normal human liver, including cytochrome P450 (CYP), multi-drug resistance-associated protein (MRP), and multi-drug protein (MDR).
    Type: Application
    Filed: August 23, 2005
    Publication date: July 13, 2006
    Applicants: Takahiro Ochiya, Effector Cell Institute, Inc.
    Inventors: Takahiro Ochiya, Takumi Teratani
  • Publication number: 20050042748
    Abstract: The object of the present invention is to provide methods for identifying factors involved in inducing the differentiation of pluripotent cells, and methods for using those factors. Using cDNA microarray technology, variations in gene expression between placebo-treated and CCl4-treated mice livers were analyzed 24 hours after treatment, and several growth factors were selected. The effects of matrix and growth factors on hepatocyte differentiation rates of ES cells were investigated. As a result, the present inventors succeeded in differentiating hepatocytes from ES cells without EB formation, using simple adherent monoculturing in media comprising several growth factors in culture dishes with two different matrices.
    Type: Application
    Filed: February 27, 2004
    Publication date: February 24, 2005
    Inventors: Takahiro Ochiya, Takumi Teratani